Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05040555Recruiting
Testing a new chemo plan for newly diagnosed high-burden lymphoma
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
Changchun, JilinAges 18–75 - NCT05086003RecruitingPhase 2
Kidney transplant with stem cell treatment to build immune tolerance
This Phase 2 study tests a combined treatment—kidney transplant plus stem cell–based immune therapy—to help the body accept the new kidney with less immune attack. You may be able to take part if you have a matching sibling donor and meet key safety and health requirements.
Petah TikvaAges 18–65 - NCT04316364RecruitingPhase 3
New immunotherapy plus chemo for resectable lung cancer
This Phase 3 trial studies whether an immunotherapy drug (SHR-1316) added to standard chemotherapy helps people live longer or delay cancer returning after surgery. It focuses on people with resectable non-small cell lung cancer (NSCLC) that has not been treated before.
Beijing, Beijing MunicipalityAges 18–70 - NCT04778657Recruiting
Study of inherited red-blood-cell disorders in France
This study follows people with inherited stomatocytosis (an inherited type of red-blood-cell disorder) to better understand these conditions. It may help researchers gather comprehensive information about diagnoses and care, which can improve future treatments.
Le Kremlin-BicêtreAges Any age - NCT04009265RecruitingPhase 3
Compare chemotherapy, chemoradiation, or surgery alone after esophageal surgery
This Phase 3 trial looks at the best next step after surgery for thoracic esophageal squamous cell cancer that has spread to nearby lymph nodes. It compares adding chemotherapy, adding chemoradiation (chemotherapy plus radiation), or not adding additional treatment right away, to see which approach works best and is safest.
Fuzhou, FujianAges 18–75 - NCT04662294RecruitingEarly Phase 1
CD70-targeted CAR T therapy for CD70-positive blood cancers
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hangzhou, ZhejiangAges Any age - NCT05124964Recruiting
Quality of life study for newly diagnosed brain germ cell tumors
This study looks at how life quality changes in children and young adults after a new diagnosis of a brain germ cell tumor. It may help doctors understand which supports improve day-to-day well-being.
BeijingAges 3–30 - NCT04969731RecruitingPhase 3
Immune cell therapy plus gemcitabine after pancreas surgery
This Phase 3 trial tests whether adding an immune cell therapy (Immuncell-LC) to the standard chemotherapy drug gemcitabine helps people with resectable pancreatic cancer after surgery. It aims to improve safety and outcomes like preventing the cancer from coming back.
Seoul, Daehak-ro, Jongno-guAges 19–80 - NCT05172739RecruitingPhase 4
Opioid-free anesthesia during lung surgery for early lung cancer
This study tests whether an opioid-free pain/anesthesia plan during elective lung surgery can reduce surgical “stress” on the body and affect the immune system. You may be eligible if you have early-stage non-small cell lung cancer and are scheduled for a specific type of surgery (VATS lobectomy).
Heraklion, CreteAges 18–80 - NCT04712305Recruiting
Urine test to predict kidney cancer response to immunotherapy
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
TaipeiAges 20 years+ - NCT05044117RecruitingPhase 3
Capecitabine pills after chemoradiation for head and neck cancer
This trial tests whether taking capecitabine pills on a steady, low schedule after standard treatment can help keep locally advanced head and neck squamous cell cancer from coming back or spreading. You may be eligible if your cancer is stage III–IV and you have finished certain radiation/chemo treatments on time, without current spread.
Guangzhou, GuangdongAges 18–70 - NCT05221372Recruiting
Sampling study for lung cancer patients on targeted pills
This trial collects blood samples from adults with advanced lung cancer that has a specific gene change and who are already taking targeted pill treatment (TKIs). The goal is to learn from these samples and how they relate to the cancer in patients on standard therapy.
RotterdamAges 18 years+ - NCT03161223RecruitingPhase 1/Phase 2
Durvalumab plus other medicines for peripheral T-cell lymphoma
This early-phase study tests how well durvalumab (an immune therapy) works with other medicines—either with or without pralatrexate, romidepsin, and oral 5-azacitidine—to treat peripheral T-cell lymphoma. It may help people with newly diagnosed or relapsed/refractory disease by strengthening the immune attack on the lymphoma.
Charlottesville, VirginiaAges 18 years+ - NCT04944563Recruiting
Segmentectomy vs lobectomy for small middle-lung lung cancer
This trial compares two types of lung surgery for certain small lung cancers in the middle part of the lung: removing a segment (segmentectomy) versus removing a whole lobe (lobectomy). It aims to see which surgery works better while balancing cancer control and lung function.
Nanjing, JiangsuAges 18–75 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT04684602RecruitingPhase 1/Phase 2
Study of stem cells for several short- and long-term illnesses
This early-stage study tests whether injections of mesenchymal stem cells can be safe and helpful for certain chronic (long-term) and acute (short-term) conditions. You might be considered if you can consent, are able to return for follow-up visits, and do not have key reasons that would make stem-cell treatment unsafe.
Culver City, CaliforniaAges 18 years+ - NCT05359796Recruiting
Study of long-term type 1 diabetes symptoms and characteristics
This study looks at what day-to-day health and medical features are like in people who have had type 1 diabetes for many years. It may help researchers better understand long-term needs in type 1 diabetes and guide future care.
Changsha, HunanAges Any age - NCT04065321Recruiting
Blood test for tumor cells in certain early breast cancers
This trial looks at a blood test that may detect “circulating tumor cells” (cancer cells that can travel in the bloodstream) in people with a specific type of breast cancer. It may help doctors better track the disease and guide treatment for people whose tumors have certain hormone and growth-factor features.
Shenyang, LiaoningAges 18–60 - NCT04807673RecruitingPhase 3
Pembrolizumab before surgery versus chemoradiation for esophageal cancer
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75 - NCT05227534Recruiting
Test for early cancer signals in people without symptoms
This trial checks whether a blood test can detect early signs of multiple cancers in people who feel well. It may help find cancer earlier, when treatment is more likely to work.
Chengdu, SichuanAges 40–75 - NCT05469022RecruitingPhase 2
Lazertinib before lung surgery for EGFR-mutant lung cancer
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
SeoulAges 19 years+ - NCT05471752Recruiting
Study of special cells taken during orthopedic surgery
This study collects small cell samples from certain body tissues during planned orthopedic surgeries. The researchers will study these cells to understand their potential use in future treatments and to see if using them is safe and helpful.
MilanAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.